Do analysts prefer TVRD or ADXN?

Tvardi Therapeutics presently has a consensus price target of $18.00, suggesting a potential upside of 1,647.57%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Tvardi Therapeutics is more favorable than Addex Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tvardi Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78 Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TVRD or ADXN more profitable?

Tvardi Therapeutics' return on equity of -145.40% beat Addex Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tvardi Therapeutics N/A -145.40% -91.11% Addex Therapeutics N/A -174.44% -126.47%

Does the media refer more to TVRD or ADXN?

In the previous week, Addex Therapeutics had 2 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 4 mentions for Addex Therapeutics and 2 mentions for Tvardi Therapeutics. Tvardi Therapeutics' average media sentiment score of 0.00 equaled Addex Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tvardi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Addex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ADXN or KPTI?

Karyopharm Therapeutics has a consensus target price of $11.50, suggesting a potential upside of 1,800.83%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Karyopharm Therapeutics is more favorable than Addex Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Karyopharm Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.57

Do analysts prefer ADXN or CLRB?

Cellectar Biosciences has a consensus price target of $11.00, suggesting a potential upside of 658.62%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Cellectar Biosciences is more favorable than Addex Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cellectar Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80

Is ADXN or CLRB more profitable?

Addex Therapeutics' return on equity of -174.44% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Addex Therapeutics N/A -174.44% -126.47% Cellectar Biosciences N/A -185.35% -115.42%

Does the media prefer ADXN or CLRB?

In the previous week, Addex Therapeutics had 2 more articles in the media than Cellectar Biosciences. MarketBeat recorded 4 mentions for Addex Therapeutics and 2 mentions for Cellectar Biosciences. Cellectar Biosciences' average media sentiment score of 0.75 beat Addex Therapeutics' score of 0.00 indicating that Cellectar Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Addex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cellectar Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ADXN or BFRI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer ADXN or BFRI?

In the previous week, Biofrontera had 2 more articles in the media than Addex Therapeutics. MarketBeat recorded 6 mentions for Biofrontera and 4 mentions for Addex Therapeutics. Biofrontera's average media sentiment score of 0.55 beat Addex Therapeutics' score of 0.00 indicating that Biofrontera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Addex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biofrontera 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ADXN or CTXR?

Citius Pharmaceuticals has a consensus price target of $5.00, suggesting a potential upside of 901.20%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Citius Pharmaceuticals is more favorable than Addex Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Citius Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Is ADXN or CTXR more profitable?

Citius Pharmaceuticals' return on equity of -59.57% beat Addex Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Addex Therapeutics N/A -174.44% -126.47% Citius Pharmaceuticals N/A -59.57% -34.47%

Does the media prefer ADXN or CTXR?

In the previous week, Addex Therapeutics had 2 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 4 mentions for Addex Therapeutics and 2 mentions for Citius Pharmaceuticals. Addex Therapeutics' average media sentiment score of 0.00 equaled Citius Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Addex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Citius Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Addex Therapeutics (ADXN) Competitors

$3.11 -0.07 (-2.20%)

Closing price 10/9/2026 03:58 PM Eastern

Extended Trading

$3.10 0.00 (-0.16%)

As of 10/9/2026 05:35 PM Eastern

Compare

ADXN vs. TVRD, KPTI, CLRB, BFRI, and CTXR

Should you buy Addex Therapeutics stock or one of its competitors? Addex Therapeutics's main competitors and comparable companies include Tvardi Therapeutics (TVRD), Karyopharm Therapeutics (KPTI), Cellectar Biosciences (CLRB), Biofrontera (BFRI), and Citius Pharmaceuticals (CTXR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Addex Therapeutics compare to Tvardi Therapeutics?

Tvardi Therapeutics (NASDAQ:TVRD) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

Tvardi Therapeutics' return on equity of -145.40% beat Addex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tvardi Therapeutics	N/A	-145.40%	-91.11%
Addex Therapeutics	N/A	-174.44%	-126.47%

In the previous week, Addex Therapeutics had 2 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 4 mentions for Addex Therapeutics and 2 mentions for Tvardi Therapeutics. Tvardi Therapeutics' average media sentiment score of 0.00 equaled Addex Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tvardi Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Addex Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Addex Therapeutics has lower revenue, but higher earnings than Tvardi Therapeutics. Addex Therapeutics is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tvardi Therapeutics	$7.14M	1.92	-$18.21M	-$2.79	N/A
Addex Therapeutics	$210K	18.22	-$8.12M	-$5.94	N/A

44.7% of Tvardi Therapeutics shares are owned by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are owned by institutional investors. 7.4% of Tvardi Therapeutics shares are owned by company insiders. Comparatively, 15.0% of Addex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Tvardi Therapeutics has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market. Comparatively, Addex Therapeutics has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market.

Tvardi Therapeutics presently has a consensus price target of $18.00, suggesting a potential upside of 1,647.57%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Tvardi Therapeutics is more favorable than Addex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Tvardi Therapeutics beats Addex Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Addex Therapeutics compare to Karyopharm Therapeutics?

Addex Therapeutics (NASDAQ:ADXN) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

Karyopharm Therapeutics has a consensus target price of $11.50, suggesting a potential upside of 1,800.83%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Karyopharm Therapeutics is more favorable than Addex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Karyopharm Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

16.1% of Addex Therapeutics shares are held by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are held by institutional investors. 15.0% of Addex Therapeutics shares are held by company insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Addex Therapeutics has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -153.28%. Karyopharm Therapeutics' return on equity of 0.00% beat Addex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Addex Therapeutics	N/A	-174.44%	-126.47%
Karyopharm Therapeutics	-153.28%	N/A	-145.18%

In the previous week, Addex Therapeutics had 3 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 4 mentions for Addex Therapeutics and 1 mentions for Karyopharm Therapeutics. Addex Therapeutics' average media sentiment score of 0.00 beat Karyopharm Therapeutics' score of -0.33 indicating that Addex Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Addex Therapeutics	Neutral
Karyopharm Therapeutics	Neutral

Addex Therapeutics has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market.

Addex Therapeutics has higher earnings, but lower revenue than Karyopharm Therapeutics. Addex Therapeutics is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addex Therapeutics	$210K	18.22	-$8.12M	-$5.94	N/A
Karyopharm Therapeutics	$146.07M	0.09	-$196.04M	-$13.09	N/A

Summary

Addex Therapeutics beats Karyopharm Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Addex Therapeutics compare to Cellectar Biosciences?

Addex Therapeutics (NASDAQ:ADXN) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

In the previous week, Addex Therapeutics had 2 more articles in the media than Cellectar Biosciences. MarketBeat recorded 4 mentions for Addex Therapeutics and 2 mentions for Cellectar Biosciences. Cellectar Biosciences' average media sentiment score of 0.75 beat Addex Therapeutics' score of 0.00 indicating that Cellectar Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Addex Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cellectar Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cellectar Biosciences has a consensus price target of $11.00, suggesting a potential upside of 658.62%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Cellectar Biosciences is more favorable than Addex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Addex Therapeutics has higher revenue and earnings than Cellectar Biosciences. Addex Therapeutics is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addex Therapeutics	$210K	18.22	-$8.12M	-$5.94	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$3.84	N/A

Addex Therapeutics has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market.

16.1% of Addex Therapeutics shares are held by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are held by institutional investors. 15.0% of Addex Therapeutics shares are held by insiders. Comparatively, 2.6% of Cellectar Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Addex Therapeutics' return on equity of -174.44% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Addex Therapeutics	N/A	-174.44%	-126.47%
Cellectar Biosciences	N/A	-185.35%	-115.42%

Summary

Cellectar Biosciences beats Addex Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Addex Therapeutics compare to Biofrontera?

Addex Therapeutics (NASDAQ:ADXN) and Biofrontera (NASDAQ:BFRI) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

In the previous week, Biofrontera had 2 more articles in the media than Addex Therapeutics. MarketBeat recorded 6 mentions for Biofrontera and 4 mentions for Addex Therapeutics. Biofrontera's average media sentiment score of 0.55 beat Addex Therapeutics' score of 0.00 indicating that Biofrontera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Addex Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biofrontera	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Addex Therapeutics has a net margin of 0.00% compared to Biofrontera's net margin of -13.78%. Biofrontera's return on equity of -145.81% beat Addex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Addex Therapeutics	N/A	-174.44%	-126.47%
Biofrontera	-13.78%	-145.81%	-31.30%

Addex Therapeutics has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market. Comparatively, Biofrontera has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market.

16.1% of Addex Therapeutics shares are held by institutional investors. Comparatively, 10.1% of Biofrontera shares are held by institutional investors. 15.0% of Addex Therapeutics shares are held by company insiders. Comparatively, 8.1% of Biofrontera shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Addex Therapeutics has higher earnings, but lower revenue than Biofrontera. Biofrontera is trading at a lower price-to-earnings ratio than Addex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addex Therapeutics	$210K	18.22	-$8.12M	-$5.94	N/A
Biofrontera	$46.18M	0.31	-$10.54M	-$0.45	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Biofrontera beats Addex Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Addex Therapeutics compare to Citius Pharmaceuticals?

Addex Therapeutics (NASDAQ:ADXN) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Citius Pharmaceuticals has a consensus price target of $5.00, suggesting a potential upside of 901.20%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Citius Pharmaceuticals is more favorable than Addex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Addex Therapeutics has higher revenue and earnings than Citius Pharmaceuticals. Addex Therapeutics is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addex Therapeutics	$210K	18.22	-$8.12M	-$5.94	N/A
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$1.67	N/A

16.1% of Addex Therapeutics shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 15.0% of Addex Therapeutics shares are held by insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Addex Therapeutics had 2 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 4 mentions for Addex Therapeutics and 2 mentions for Citius Pharmaceuticals. Addex Therapeutics' average media sentiment score of 0.00 equaled Citius Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Addex Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Citius Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Citius Pharmaceuticals' return on equity of -59.57% beat Addex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Addex Therapeutics	N/A	-174.44%	-126.47%
Citius Pharmaceuticals	N/A	-59.57%	-34.47%

Addex Therapeutics has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.

Summary

Citius Pharmaceuticals beats Addex Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Addex Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADXN vs. The Competition

Export

Metric	Addex Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.92M	$12.32B	$7.16B	$13.21B
Dividend Yield	N/A	2.64%	2.53%	16.37%
P/E Ratio	-0.52	797.58	274.15	26.16
Price / Sales	18.22	939.82	635.98	113.06
Price / Cash	N/A	85.97	76.38	53.09
Price / Book	0.67	10.71	11.21	6.34
Net Income	-$8.12M	$2.84B	$3.50B	$381.90M
7 Day Performance	1.30%	-0.93%	-0.90%	-1.41%
1 Month Performance	-8.26%	-4.91%	-4.44%	-3.48%
1 Year Performance	-65.02%	-4.13%	6.96%	1.16%

Addex Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADXN Addex Therapeutics	0.3108 of 5 stars	$3.11 -2.2%	N/A	-65.7%	$3.92M	$210K	N/A	3	News Coverage Short Interest Increase Gap Up
TVRD Tvardi Therapeutics	2.8951 of 5 stars	$1.10 +1.9%	$18.00 +1,536.4%	-97.6%	$14.67M	$7.14M	N/A	80
KPTI Karyopharm Therapeutics	3.256 of 5 stars	$0.65 -0.8%	$11.50 +1,682.9%	-89.6%	$14.63M	$146.07M	N/A	228
CLRB Cellectar Biosciences	3.7745 of 5 stars	$1.51 flat	$11.00 +628.5%	-69.6%	$14.27M	N/A	N/A	11
BFRI Biofrontera	1.688 of 5 stars	$0.94 +0.4%	N/A	-6.7%	$13.89M	$46.18M	N/A	94	News Coverage Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADXN) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Addex Therapeutics (ADXN) Competitors

ADXN vs. TVRD, KPTI, CLRB, BFRI, and CTXR

How does Addex Therapeutics compare to Tvardi Therapeutics?

Summary

How does Addex Therapeutics compare to Karyopharm Therapeutics?

Summary

How does Addex Therapeutics compare to Cellectar Biosciences?

Summary

How does Addex Therapeutics compare to Biofrontera?

Summary

How does Addex Therapeutics compare to Citius Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADXN vs. The Competition

Addex Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Addex Therapeutics (ADXN) Competitors

ADXN vs. TVRD, KPTI, CLRB, BFRI, and CTXR

How does Addex Therapeutics compare to Tvardi Therapeutics?

Is TVRD or ADXN more profitable?

Does the media refer more to TVRD or ADXN?

Which has stronger earnings & valuation, TVRD or ADXN?

Do insiders & institutionals have more ownership in TVRD or ADXN?

Which has more volatility & risk, TVRD or ADXN?

Do analysts prefer TVRD or ADXN?

Summary

How does Addex Therapeutics compare to Karyopharm Therapeutics?

Do analysts recommend ADXN or KPTI?

Do insiders & institutionals hold more shares of ADXN or KPTI?

Is ADXN or KPTI more profitable?

Does the media prefer ADXN or KPTI?

Which has more volatility and risk, ADXN or KPTI?

Which has stronger earnings and valuation, ADXN or KPTI?

Summary

How does Addex Therapeutics compare to Cellectar Biosciences?

Does the media prefer ADXN or CLRB?

Do analysts prefer ADXN or CLRB?

Which has better valuation & earnings, ADXN or CLRB?

Which has more volatility and risk, ADXN or CLRB?

Do insiders and institutionals have more ownership in ADXN or CLRB?

Is ADXN or CLRB more profitable?

Summary

How does Addex Therapeutics compare to Biofrontera?

Does the media prefer ADXN or BFRI?

Is ADXN or BFRI more profitable?

Which has more risk & volatility, ADXN or BFRI?

Do institutionals & insiders have more ownership in ADXN or BFRI?

Which has higher earnings and valuation, ADXN or BFRI?

Do analysts prefer ADXN or BFRI?

Summary

How does Addex Therapeutics compare to Citius Pharmaceuticals?

Do analysts rate ADXN or CTXR?

Which has preferable valuation and earnings, ADXN or CTXR?

Do institutionals and insiders have more ownership in ADXN or CTXR?

Does the media prefer ADXN or CTXR?

Is ADXN or CTXR more profitable?

Which has more risk and volatility, ADXN or CTXR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADXN vs. The Competition

Addex Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools